Detalles de la búsqueda
1.
Risk markers of incident atrial fibrillation in patients with coronary heart disease.
Am Heart J
; 233: 92-101, 2021 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-33400910
2.
Rationale and design of ApoA-I Event Reducing in Ischemic Syndromes II (AEGIS-II): A phase 3, multicenter, double-blind, randomized, placebo-controlled, parallel-group study to investigate the efficacy and safety of CSL112 in subjects after acute myocardial infarction.
Am Heart J
; 231: 121-127, 2021 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-33065120
3.
Clinical features and outcomes of patients with type 2 myocardial infarction: Insights from the Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome (TRACER) trial.
Am Heart J
; 196: 28-35, 2018 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-29421012
4.
Visit-to-visit variability of blood pressure and cardiovascular outcomes in patients with stable coronary heart disease. Insights from the STABILITY trial.
Eur Heart J
; 38(37): 2813-2822, 2017 Oct 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-28575274
5.
Trade-off of myocardial infarction vs. bleeding types on mortality after acute coronary syndrome: lessons from the Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome (TRACER) randomized trial.
Eur Heart J
; 38(11): 804-810, 2017 Mar 14.
Artículo
en Inglés
| MEDLINE | ID: mdl-28363222
6.
Atherothrombotic Risk Stratification and the Efficacy and Safety of Vorapaxar in Patients With Stable Ischemic Heart Disease and Previous Myocardial Infarction.
Circulation
; 134(4): 304-13, 2016 Jul 26.
Artículo
en Inglés
| MEDLINE | ID: mdl-27440003
7.
Darapladib for preventing ischemic events in stable coronary heart disease.
N Engl J Med
; 370(18): 1702-11, 2014 May 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-24678955
8.
Growth Differentiation Factor 15 Predicts All-Cause Morbidity and Mortality in Stable Coronary Heart Disease.
Clin Chem
; 63(1): 325-333, 2017 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-27811204
9.
The impact of atrial fibrillation type on the risk of thromboembolism, mortality, and bleeding: a systematic review and meta-analysis.
Eur Heart J
; 37(20): 1591-602, 2016 May 21.
Artículo
en Inglés
| MEDLINE | ID: mdl-26888184
10.
Corrigendum to 'National Heart Foundation of Australia & Cardiac Society of Australia and New Zealand: Australian Clinical Guidelines for the Management of Acute Coronary Syndromes 2016' Heart Lung and Circulation volume 25, (2016) 898 - 952.
Heart Lung Circ
; 26(10): 1117, 2017 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-28867028
11.
Efficacy and Safety of Vorapaxar With and Without a Thienopyridine for Secondary Prevention in Patients With Previous Myocardial Infarction and No History of Stroke or Transient Ischemic Attack: Results from TRA 2°P-TIMI 50.
Circulation
; 132(20): 1871-9, 2015 Nov 17.
Artículo
en Inglés
| MEDLINE | ID: mdl-26338971
12.
Albuminuria and cardiovascular events in patients with acute coronary syndromes: Results from the TRACER trial.
Am Heart J
; 178: 1-8, 2016 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-27502846
13.
Effect of age on efficacy and safety of vorapaxar in patients with non-ST-segment elevation acute coronary syndrome: Insights from the Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome (TRACER) trial.
Am Heart J
; 178: 176-84, 2016 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-27502866
14.
Arterial access site and outcomes in patients undergoing percutaneous coronary intervention with and without vorapaxar.
Catheter Cardiovasc Interv
; 88(2): 163-73, 2016 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-26698636
15.
Effect of Losmapimod on Cardiovascular Outcomes in Patients Hospitalized With Acute Myocardial Infarction: A Randomized Clinical Trial.
JAMA
; 315(15): 1591-9, 2016 Apr 19.
Artículo
en Inglés
| MEDLINE | ID: mdl-27043082
16.
Losmapimod, a novel p38 mitogen-activated protein kinase inhibitor, in non-ST-segment elevation myocardial infarction: a randomised phase 2 trial.
Lancet
; 384(9949): 1187-95, 2014 Sep 27.
Artículo
en Inglés
| MEDLINE | ID: mdl-24930728
17.
Thrombin-receptor antagonist vorapaxar in acute coronary syndromes.
N Engl J Med
; 366(1): 20-33, 2012 Jan 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-22077816
18.
Prasugrel versus clopidogrel for acute coronary syndromes without revascularization.
N Engl J Med
; 367(14): 1297-309, 2012 Oct 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-22920930
19.
Rationale and design of the LosmApimod To Inhibit p38 MAP kinase as a TherapeUtic target and moDify outcomes after an acute coronary syndromE trial.
Am Heart J
; 169(5): 622-630.e6, 2015 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-25965709
20.
Elderly patients with acute coronary syndromes managed without revascularization: insights into the safety of long-term dual antiplatelet therapy with reduced-dose prasugrel versus standard-dose clopidogrel.
Circulation
; 128(8): 823-33, 2013 Aug 20.
Artículo
en Inglés
| MEDLINE | ID: mdl-23852610